glp-1 receptor agonists and cancer risk in adults with obesity GLP-1s may reduce related risk, new research shows. Across large observational cohorts, they were linked to reduced rates of endometrial, liver, colorectal, other cancers. Learn more at the link Obesity is now responsible for

Beyond Sermorelin, our goal-based protocol menu covers skin quality and anti-aging support, metabolic function and fat loss, injury recovery and tissue repair, muscle development, inflammation balance, and performance optimization

The combination of both CoQ10 and rich antioxidants can support egg quality and fertility outcomes

Forty subjects were divided into a test group (taking four tablets daily) and a placebo group

Available from: Butler J, Shah SJ, Petrie MC, Borlaug BA, Abildstrm SZ, Davies MJ et al (2024) Semaglutide versus placebo in people with obesity-related heart failure with preserved ejection fraction: a pooled analysis of the STEP-HFpEF and STEP-HFpEF DM randomised trials